AYESHA GULISTAN: Open Payments
NPI 1609105386 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,426 in 57 payments from 17 companies in 2025. Trend: 2023 $841 · 2024 $1,106 · 2025 $1,426
Food & beverage: $1,426
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $214 |
| AstraZeneca Pharmaceuticals LP | 10 | $184 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $162 |
| ABBVIE INC. | 6 | $130 |
| Corcept Therapeutics | 1 | $125 |
| Inspire Medical Systems, Inc. | 1 | $101 |
| PFIZER INC. | 5 | $99 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $92 |
| Lilly USA, LLC | 5 | $90 |
| Astellas Pharma US Inc | 3 | $68 |
Products named: Kerendia, Korlym, Ozempic, INSPIRE, XIFAXAN, VRAYLAR, JARDIANCE, AIRSUPRA.
Industry payments across MD — which companies pay providers there.
